Aclf Management

Overview

Definition

Acute-on-chronic liver failure (ACLF) is a syndrome in patients with chronic liver disease, usually but not always cirrhosis, characterized by an acute decompensation (AD) event, development of organ failure(s) (liver, kidney, brain, coagulation, circulation, respiration), and high 28-day and 90-day mortality.

The European Association for the Study of the Liver (EASL) and the American Association for the Study of Liver Diseases (AASLD) definitions vary slightly, but the common criteria include: 1. Acute hepatic insult. 2. Decompensated liver disease (ascites, encephalopathy, jaundice). 3. Development of single or multiple organ failures (OFs), typically defined by the CLIF-C Organ Failure score (CLIF-C OFs).

Epidemiology

• Incidence: ACLF develops in approximately 10-30% of patients hospitalized for acute decompensation of cirrhosis.
• Mortality: High. 28-day mortality ranges from 15% (ACLF Grade 1) to over 70% (ACLF Grade 3). 90-day mortality exceeds 80% in Grade 3.
• Demographics: The majority of patients are those with underlying alcohol-related liver disease (ALD) or viral hepatitis B (HBV), though recent trends show increasing incidence related to Non-Alcoholic Steatohepatitis (NASH).

Classification

ACLF is primarily classified using the CLIF-C ACLF Score derived from the Chronic Liver Failure Consortium (CLIF-C) data, based on the number and type of organ failures (OFS) and creatinine/White Blood Cell (WBC) count.

CLIF-C ACLF Grade	Organ Failures (OFs)	90-Day Mortality (Approx.)
Grade 1	Single renal failure (Creatinine $\ge 1.5 \text{ mg/dL}$ or requiring RRT) OR Single non-renal failure (Brain, Circulatory, Respiratory, Coagulation or Liver OF) AND serum Creatinine $1.5 \text{ mg/dL}$ or Hepatic Encephalopathy (HE) Grade $1 \text{ or } 2$	23%
Grade 2	Two organ failures	35%
Grade 3	Three or more organ failures	$\ge 70\%$

Specific Organ Failure Criteria (CLIF-C OFs Score): 1. Kidney: Creatinine $\ge 2.0 \text{ mg/dL}$ or requirement for Renal Replacement Therapy (RRT). 2. Liver: Bilirubin $\ge 12 \text{ mg/dL}$. 3. Coagulation: INR $\ge 2.5$ (without anticoagulant therapy). 4. Brain (HE): Grade $\ge 3$ according to West Haven Criteria. 5. Circulation (Shock): Requirement for Vasopressors (e.g., Norepinephrine) to maintain MAP $\ge 65 \text{ mmHg}$. 6. Respiration: $\text{PaO}_2 / \text{FiO}_2$ ratio $\le 200$ (with ventilation) or $\le 300$ (without ventilation).

Pathophysiology

Mechanism

ACLF is driven by a massive, systemic inflammatory response (SIRS) triggered by an acute precipitating event (e.g., bacterial infection, severe alcoholic hepatitis, acute viral flare).

1. PAMP/DAMP Release: Acute insult leads to the release of Pathogen-Associated Molecular Patterns (PAMPs, e.g., LPS from translocating bacteria) and Danger-Associated Molecular Patterns (DAMPs, e.g., necrotic hepatocytes).
2. Immune Activation (SIRS): Activation of Kupffer cells and macrophages, leading to the massive release of pro-inflammatory cytokines ($\text{TNF}-\alpha, \text{IL}-6, \text{IL}-1\beta$).
3. Endothelial Dysfunction: Systemic inflammation causes endothelial injury, leading to capillary leak, microcirculatory dysfunction, and tissue hypoperfusion despite potential hyperdynamic circulation.
4. Organ Failure: The combination of hypoperfusion, inflammation, and direct cellular toxicity overwhelms the reserve of multiple organs (kidneys, lungs, brain), resulting in sequential organ failure.
5. Immune Exhaustion (CIRS): Following SIRS, a phase of compensatory anti-inflammatory response syndrome (CIRS) often occurs, leaving patients immunocompromised and highly susceptible to secondary nosocomial infections, which further propagate ACLF.

Risk Factors

• Underlying Liver Disease: Cirrhosis (especially with prior decompensation), advanced fibrosis, alcohol-related liver disease (most common etiology in Western countries).
• Precipitating Events:
  • Infection (most common, especially Spontaneous Bacterial Peritonitis (SBP), pneumonia, UTI).
  • Severe Alcoholic Hepatitis (SAH).
  • Acute viral flares (e.g., HBV reactivation, HEV).
  • Gastrointestinal Bleeding (GIB).
  • Iatrogenic injury (e.g., Nephrotoxic drugs, extensive surgery).

Protective Factors

• Absence of Severe Cirrhosis: Patients with preserved synthetic function and less severe portal hypertension are less prone to developing ACLF.
• Vaccination Status: Protection against influenza and pneumococcus.
• Control of Underlying Etiology: Sustained abstinence in ALD, effective antiviral treatment (HBV, HCV).
• Prophylaxis: Effective SBP prophylaxis (e.g., Norfloxacin) in high-risk patients.

Clinical Presentation

Signs and Symptoms

Cardinal Features

• Rapidly Worsening Jaundice: Bilirubin $> 5 \text{ mg/dL}$ or rapidly rising.
• Ascites Refractory to Diuretics or new onset (Acute Decompensation).
• Hepatic Encephalopathy (HE): Fluctuation of mental status (often Grade 2 or higher required for ACLF OF criteria).
• Fever/Hypothermia: Sign of systemic inflammation/infection.

Early Signs

• Fatigue, anorexia, malaise.
• Oliguria (early sign of AKI).
• Mild confusion (HE Grade 1).
• Tachycardia and hypotension (early circulatory dysfunction/infection).

Advanced Signs

• Deep Coma (HE Grade 4).
• Respiratory Distress/Hypoxemia (ARDS or Hepatic Hydrothorax).
• Require Vasopressor Support (Circulatory Failure/Shock).
• Anuria/Severe AKI requiring RRT.
• Overt Bleeding (Coagulopathy OF).

Atypical Presentations

• ACLF without Overt Cirrhosis: Usually seen in severe alcoholic hepatitis or acute HBV on underlying chronic liver disease.
• "Silent" Infection: Absence of fever in profound immunosuppression, or infection localized only in the peritoneal fluid (SBP).

Physical Examination

Inspection

• Jaundice: Scleral icterus, Generalized yellow discoloration.
• Ascites: Abdominal distention, Flank dullness, Fluid wave.
• Stigmata of Chronic Liver Disease: Spider angiomata, Palmar erythema, Gynecomastia.
• Mental Status: Assessment of HE (Asterixis, Confusion, Obtundation).
• Respiratory: Tachypnea, use of accessory muscles, signs of pleural effusion/hydrothorax.

Palpation

• Abdomen: Tenderness (peritonitis, cholecystitis), Hepatosplenomegaly (depending on etiology and stage).
• Vitals: Peripheral edema, assess volume status (capillary refill, peripheral pulse quality).

Special Tests

• Paracentesis: Required for all patients with new-onset or deteriorating ascites to rule out SBP, which is a major ACLF trigger.
• Clinical HE Assessment: West Haven Criteria staging.

Diagnostic Approach

History Taking

Key Questions

• Precipitating Event: Did a recent infection, alcohol binge, or GIB occur?
• Baseline Status: Known diagnosis (cirrhosis, hepatitis type, previous decompensations)?
• Medication Review: Use of NSAIDs, recent diuretics adjustments, new medications (especially sedatives, nephrotoxins).
• Alcohol Use: Recent quantity and pattern (critical for SAH/ACLF overlap).

Red Flags

• Acute Change in Mental Status/Coma.
• Fever/Rigors.
• Oliguria/Anuria.
• Hematemesis/Melena.
• Severe Abdominal Pain.

Laboratory Tests

First-Line (Initial Diagnostic Tests)

1. Complete Blood Count (CBC) with Differential: Look for leukocytosis (Infection/SIRS) or leukopenia (sepsis/ACLF-related immune suppression).
2. Comprehensive Metabolic Panel (CMP): Electrolytes, Glucose, Creatinine (essential for AKI staging), Bilirubin (essential for Liver OF).
3. Liver Panel: AST, ALT, ALP, GGT (pattern suggests etiology, e.g., very high AST in SAH).
4. Coagulation Profile: PT/INR (essential for Coagulation OF).
5. Inflammatory Markers: C-Reactive Protein (CRP), Procalcitonin (PCT) (suggests bacterial infection).
6. Infection Workup: Blood and urine cultures; Diagnostic Paracentesis (cell count and culture).

Confirmatory (Definitive Diagnostic Tests)

• Arterial Blood Gas (ABG): Assessment of $\text{PaO}_2 / \text{FiO}_2$ (Respiratory OF), $\text{pH}$ (metabolic/lactic acidosis).
• Etiology Workup: HBV DNA, Anti-HCV, Autoimmune markers, Alcohol assessment.

Monitoring

• Daily/Twice Daily Labs (CMP, LFTs, INR) during critical phase.
• Daily monitoring of CLIF-C ACLF score and trends in individual organ failure scores (e.g., Creatinine, Bilirubin).

Imaging

Recommended (Standard Imaging Studies)

• Abdominal Ultrasound with Doppler: Assess liver size, contour (nodularity suggests cirrhosis), portal vein patency (r/o thrombosis), and presence/volume of ascites.
• Chest X-ray (CXR): Rule out pneumonia, pulmonary edema, or large pleural effusions (e.g., hepatic hydrothorax).

Advanced (Specialized Imaging when needed)

• CT Abdomen/Pelvis: If intra-abdominal source of infection is suspected (e.g., abscess, diverticulitis) or underlying malignancy.
• Head CT/MRI: If focal neurological deficits or suspicion for structural brain lesion in HE Grade 3/4.

Management

ACLF management is primarily supportive, focusing on identifying and treating the precipitating event (P), managing the acute systemic inflammation (I), and supporting failing organs (S).

Acute Management

Immediate (First-hour interventions)

1. Resuscitation: Assess ABCs (Airway, Breathing, Circulation). Ventilator support if HE Grade 4 or severe hypoxemia.
2. Fluid Management: Use balanced crystalloids (e.g., Ringer's Lactate) for volume resuscitation if hypotensive or evidence of bleeding. Caution: Avoid over-resuscitation which can worsen ascites and pulmonary issues.
3. Infection Control: Obtain cultures (Blood, Urine, Ascites Fluid). Empiric broad-spectrum antibiotics (e.g., Ceftriaxone 1g IV $\text{q}24 \text{h}$ or Piperacillin-Tazobactam) immediately if suspicion of bacterial infection (fever, leukocytosis, Grade 2/3 ACLF).

Stabilization (Early management priorities)

1. Manage Hepatic Encephalopathy (HE):
   • Stop benzodiazepines/sedatives.
   • Lactulose: Titrated based on clinical response (aim for 2-3 soft bowel movements per day). Initial dose often 30 mL $\text{q}1-2 \text{h}$ until catharsis, then 15-45 mL $\text{q}8\text{h}$ PRN.
   • Rifaximin: 550 mg BID adjunctively, especially if unresponsive to Lactulose.
2. Manage Acute Kidney Injury (AKI):
   • Identify type of AKI (Pre-renal, ATN, HRS-AKI).
   • If Hypovolemia: Albumen infusion (e.g., 1g/kg max 100g infusion after large volume paracentesis, or $1 \text{ g/kg}$/day for $\text{HRS}-\text{AKI}$ protocol).
   • If Hepatorenal Syndrome (HRS-AKI): Initiate Terlipressin (or Norepinephrine if Terlipressin unavailable) plus Albumin.
3. Address Precipitant:
   • SAH: Corticosteroids (Prednisolone 40 mg PO/day) if MELD-score $< 20-30$, Maddrey's Discriminant Function (MDF) $\ge 32$, and no uncontrolled infection/GIB.
   • HBV Flare: Initiate or optimize potent nucleos(t)ide analog therapy (e.g., Entecavir, Tenofovir).

Emergency (Crisis management)

• Circulatory Failure/Septic Shock: Use Norepinephrine as the preferred vasopressor to maintain MAP $\ge 65 \text{ mmHg}$. Goal-directed therapy.
• Severe Coagulopathy/Bleeding: Transfuse FFP/Platelets only if active bleeding or pre-procedure (INR and Platelets are markers of OF, not necessarily transfusion triggers). Maintain Platelets $> 50,000$ and Fibrinogen $> 100 \text{ mg/dL}$ in active bleeding.

Chronic Management

The overarching goal is to identify ACLF candidates who can survive to transplantation (Bridge Therapy).

Pharmacological

• Antibiotics: Targeted therapy based on cultures, followed by discontinuation or lifelong SBP prophylaxis (e.g., Ciprofloxacin, Norfloxacin) if high risk.
• Diuretic Management: Often requires hold or significant reduction in diuretics, especially if AKI/HRS develops.
• ACLF Specific: Continuation of Lactulose/Rifaximin for prevention of recurrent HE.

Non-pharmacological

• Nutritional Support: Early enteral nutrition (NG tube feeding) is preferred over parenteral where possible, especially in SAH/severe malnutrition, but requires caution due to risk of aspiration in severe HE.
• Alcohol Abstinence: Mandatory for ALD etiology.

Monitoring (Long-term follow-up)

• Dynamic ACLF Score: Repeated calculation of CLIF-C ACLF and CLIF-C ATs (Acute-on-Chronic Liver Failure score at 3-7 days) to assess treatment response and prognosis.
• Transplant Evaluation: Patients with ACLF Grade 2-3 who stabilize are urgent candidates for liver transplantation (LT) due to high recurrence and mortality risk.

Treatment Algorithms

First-Line (Primary treatment approach)

1. Immediate Resuscitation and Identify/Treat Precipitant.
2. Manage Organ Failures: Aggressive HE management (Lactulose/Rifaximin) and HRS-AKI protocol (Terlipressin/Albumin).
3. Antibiotics: Empiric followed by targeted, for a duration of $5-7 \text{ days}$ for SBP.

Second-Line (Alternative treatments)

• RRT (Dialysis): Required for Refractory AKI (Creatinine $\ge 4.0 \text{ mg/dL}$) or life-threatening electrolyte/fluid overload/acidosis.
• Plasma Exchange (PLEX): Used selectively in severe AH-ACLF (MDF $\ge 50$) as a bridge to transplant.
• Molecular Adsorbent Recirculating System (MARS) or Single-Pass Albumin Dialysis (SPAD): Limited evidence, used in some centers for bridge therapy for severe bilirubin/encephalopathy clearance.

Refractory Cases

• Early Liver Transplantation: ACLF is generally considered a short-term contraindication to LT due to high surgery risk, but sustained improvement in organ function after 3-7 days of maximal therapy is the green light. Patients who fail to improve CLIF-C ACLF score after $3-7 \text{ days}$ of optimal management have very poor prognosis, and LT should be strongly considered if eligibility criteria met.

Complications

Common

• Recurrent or Nosocomial Infections (e.g., C. difficile).
• Refractory Ascites.
• Electrolyte Imbalances (especially Hyponatremia).

Serious

• Multi-Organ Failure (MOF).
• Severe Sepsis/Septic Shock.
• Intracranial Hypertension (rare, associated with Grade 4 HE/Cerebral Edema).

Long-term

• Chronic dependence on RRT (if kidney injury is persistent).
• Cognitive impairment (following severe HE episode).
• Persistent high risk of recurrent ACLF events unless LT is performed or underlying etiology is completely reversed (e.g., long-term alcohol abstinence).

Prognosis

Factors

• CLIF-C ACLF Score: Primary predictor of short-term mortality. Scores calculated at day 3-7 (CLIF-C $\text{ACLFs} / \text{ATs}$) are superior predictors of 90-day survival than baseline scores.
• Number of Organ Failures: Directly correlates with mortality (higher number = worse outcome).
• Etiology: Non-alcohol related ACLF often has slightly better prognosis than AH-ACLF, provided the insult is controlled.
• WBC Count: High baseline WBC ($\ge 10,000 \text{ cells}/\text{mm}^3$) is associated with worse outcome.

Survival

• 28-day Survival: ACLF Grade 1: $\sim 77\%$; ACLF Grade 2: $\sim 65\%$; ACLF Grade 3: $\sim 30\%$.
• 90-day Survival: Grade 1: $\sim 55\%$; Grade 2: $\sim 40\%$; Grade 3: $\sim 15\%$.

Quality of Life

Survivors often require extensive rehabilitation; health-related Quality of Life (HRQoL) remains significantly lower than non-ACLF cirrhotic controls, especially in the absence of LT.

Prevention

Primary

• Alcohol Cessation: Strict abstinence is paramount.
• Vaccination: Influenza and Pneumococcal vaccines.
• Infection Control: Hand hygiene, avoidance of high-risk environments.

Secondary

• SBP Prophylaxis: Norfloxacin $400 \text{ mg}$ daily for high-risk patients (Ascitic fluid protein $< 1.5 \text{ g/dL}$ plus $\text{Child-Pugh} \ge 9$ or $\text{Creatinine} \ge 1.2$).
• Screening and Management of Underlying Disease: Effective antiviral therapy for HBV/HCV.

Tertiary

• Timely Referral for LT Evaluation: Preventing recurrence and MOF progression in survivors of ACLF Grade 2-3.
• Aggressive Management of Acute Decompensation: Rapid diagnosis and treatment of potential ACLF triggers (infection, bleeding).

Special Populations

Geriatric

• Increased susceptibility to infections.
• Decreased physiological reserve, leading to rapidly developing OFs.
• Higher risk of medication-related adverse effects (e.g., NSAID AKI, diuretic-induced hyponatremia).

Pregnancy

• Requires careful monitoring of fluid status and blood pressure.
• Specific etiologies (e.g., $\text{HELLP}$ syndrome, Acute Fatty Liver of Pregnancy) must be considered and distinguished from ACLF in patients with pre-existing CLD.

Comorbidities

• Cardiovascular Disease: Extreme caution with volume loading; monitor for Hepatic Cardiomyopathy.
• Diabetes: Meticulous glucose control is required as hyperglycemia worsens outcomes and immune function.

Clinical Pearls

Diagnostic

1. Paracentesis is Non-negotiable: Perform on every decompensated patient upon admission to rule out SBP, even if afebrile.
2. ACLF Definition is Dynamic: Do not wait for 3 organs to fail; Grade 1 ACLF requires aggressive management similar to severe sepsis anywhere else.

Treatment

1. Dose Albumin Appropriately: If giving Terlipressin for HRS-AKI, co-administer Albumin. Standard regimen: $1 \text{ g/kg}$ on day 1 (max $100 \text{ g}$), followed by $20-40 \text{ g}$ daily.
2. Avoid $H_2$ Blockers or PPIs unnecessarily: These increase risk of SBP and C. difficile infection. Use only if clear indication (e.g., active GIB).
3. Corticosteroids in SAH-ACLF: Ensure infection is ruled out/controlled before starting steroids. Re-assess failure to respond via Lille score at Day 7.

Pitfalls

• Mistaking ACLF for Chronic Decompensation: Failure to recognize the systemic inflammation and high short-term mortality associated with ACLF leads to delayed transfer or suboptimal critical care.
• Inappropriate Use of Diuretics: Continuing high-dose diuretics in the face of AKI or borderline circulation will exacerbate AKI/HRS.
• Empiric Cephalosporin Resistance: Many centers have high rates of Multi-Drug Resistant (MDR) infections in ACLF patients. Consider carbapenems or $\text{Pip-Taz}$ if high local resistance, prior exposure, or recent hospitalization.

Recent Updates

Guidelines

• EASL 2022: Emphasize the importance of early diagnosis using the CLIF-C criteria and the high priority for urgent liver transplantation evaluation in ACLF Grade 2 and 3 survivors following initial stabilization.
• AASLD/ACG: Increasingly recognizing the systemic inflammatory nature of ACLF and reinforcing the use of Terlipressin plus Albumin for HRS-AKI management.

Evidence

• Role of Inflammation: Recent research highlights the CLIF-C ACLF score's reliance on WBC count and CRP, strong indicators of the systemic inflammation that drives multi-organ failure.
• Terlipressin Efficacy: The $\text{CONFIRM}$ trial and its subsequent analyses confirmed that Terlipressin significantly increases the rate of $\text{HRS}-\text{AKI}$ reversal compared to placebo, although with vigilance for ischemic events (less common with the continuous infusion approach).

Controversies

• LT in Active ACLF: Debate remains on the optimal timing and selection criteria for LT in patients with ACLF Grade 3. While survival is low without transplant, perioperative mortality remains substantial. Decisions are highly individualized based on trajectory of CLIF-C score improvement.
• Steroids in ACLF Due to SAH: The utility of corticosteroids is often limited by confounding ACLF factors (infection, pre-existing kidney disease). More personalized approaches using the Lille score are adopted.

Key References

Guidelines

• EASL Clinical Practice Guidelines on Decompensated Cirrhosis and ACLF: Definition, Clinical Characteristics and Management (2022).
• AASLD Guidance: The Management of Acute Kidney Injury in Cirrhosis (2015, pending update).

Studies

• Moreau et al. $\text{Acute-on-chronic}$ liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis (CLIF-C Consortium, 2013).
• Jalan R et al. CLIF-C ACLF in patients with acute decompensation of cirrhosis: the CLIF-C ACLF score. J Hepatology, 2014.
• Wong F et al. Terlipressin Plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome (CONFIRM Trial). N Engl J Med, 2021.

Reviews

• Jalan R et al. Pathophysiological Basis of ACLF. J Hepatology, 2019.

---

Disclaimer: This reference provides evidence-based medical information for educational and clinical guidance purposes. It is not a substitute for professional medical judgment. Decision-making in Acute-on-Chronic Liver Failure (ACLF) requires immediate critical care consultation, specialized expertise, and careful consideration of the individual patient's condition, resource availability, and local hospital protocols. Drug dosages should always be verified against official prescribing information.